Literature DB >> 31357143

Systemic therapy for brain metastases.

Jonathan W Rick1, Maryam Shahin1, Ankush Chandra1, Cecilia Dalle Ore1, John K Yue1, Alan Nguyen1, Garima Yagnik1, Soumya Sagar1, Saman Arfaie1, Manish K Aghi2.   

Abstract

Metastases from cells outside of the central nervous system are the most common cancer found in the brain and are commonly associated with poor prognosis. Although cancer treatment is improving overall, central nervous system metastases are becoming more prevalent and require finesse to properly treat. Physicians must consider the biology of the primary tumor and the complex neurological environment that the metastasis resides in. This can be further complicated by the fact that the practice of cancer management is constantly evolving and therapy that works outside of the blood-brain barrier may not be effective inside of it. Therefore, this review seeks to update the reader on recent advancements made on the three most common sources of brain metastases: lung cancer, breast cancer, and melanoma. Each of these malignancies has been the subject of intriguing and novel avenues of therapy which are reviewed here.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Breast cancer; Lung cancer; Melanoma; Metastasis; Systemic therapy

Mesh:

Year:  2019        PMID: 31357143      PMCID: PMC6746616          DOI: 10.1016/j.critrevonc.2019.07.012

Source DB:  PubMed          Journal:  Crit Rev Oncol Hematol        ISSN: 1040-8428            Impact factor:   6.312


  68 in total

1.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.

Authors:  Michael A Davies; Philippe Saiag; Caroline Robert; Jean-Jacques Grob; Keith T Flaherty; Ana Arance; Vanna Chiarion-Sileni; Luc Thomas; Thierry Lesimple; Laurent Mortier; Stergios J Moschos; David Hogg; Iván Márquez-Rodas; Michele Del Vecchio; Céleste Lebbé; Nicolas Meyer; Ying Zhang; Yingjie Huang; Bijoyesh Mookerjee; Georgina V Long
Journal:  Lancet Oncol       Date:  2017-06-04       Impact factor: 41.316

Review 2.  Chemotherapy for brain metastases of lung cancer: a review.

Authors:  P E Postmus; E F Smit
Journal:  Ann Oncol       Date:  1999-07       Impact factor: 32.976

Review 3.  A critique of the role of the blood-brain barrier in the chemotherapy of human brain tumors.

Authors:  D J Stewart
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

4.  Prospective evaluation of the effect on initial brain metastases from small cell lung cancer of platinum-etoposide based induction chemotherapy followed by an alternating multidrug regimen.

Authors:  P E Kristjansen; P Soelberg Sørensen; M Skov Hansen; H H Hansen
Journal:  Ann Oncol       Date:  1993-08       Impact factor: 32.976

5.  Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer.

Authors:  James W Welsh; Ritsuko Komaki; Arya Amini; Mark F Munsell; Wyatt Unger; Pamela K Allen; Joe Y Chang; Jeffrey S Wefel; Susan L McGovern; Linda L Garland; Su S Chen; Jamie Holt; Zhongxing Liao; Paul Brown; Erik Sulman; John V Heymach; Edward S Kim; Baldassarre Stea
Journal:  J Clin Oncol       Date:  2013-01-22       Impact factor: 44.544

6.  Activity of T-DM1 in Her2-positive breast cancer brain metastases.

Authors:  Rupert Bartsch; Anna S Berghoff; Ursula Vogl; Margaretha Rudas; Elisabeth Bergen; Peter Dubsky; Karin Dieckmann; Katja Pinker; Zsuzsanna Bago-Horvath; Arik Galid; Leopold Oehler; Christoph C Zielinski; Michael Gnant; Guenther G Steger; Matthias Preusser
Journal:  Clin Exp Metastasis       Date:  2015-08-25       Impact factor: 5.150

7.  Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases: a phase II study (CTONG-0803).

Authors:  Y-L Wu; C Zhou; Y Cheng; S Lu; G-Y Chen; C Huang; Y-S Huang; H-H Yan; S Ren; Y Liu; J-J Yang
Journal:  Ann Oncol       Date:  2012-11-04       Impact factor: 32.976

Review 8.  HER2-positive breast cancer: Current and new therapeutic strategies.

Authors:  Santiago Escrivá-de-Romaní; Miriam Arumí; Meritxell Bellet; Cristina Saura
Journal:  Breast       Date:  2018-04-06       Impact factor: 4.380

9.  The response of cerebral metastases in small cell lung cancer to systemic chemotherapy.

Authors:  C J Twelves; R L Souhami; P G Harper; C M Ash; S G Spiro; H M Earl; J S Tobias; H Quinn; D M Geddes
Journal:  Br J Cancer       Date:  1990-01       Impact factor: 7.640

Review 10.  Targeted Therapies for Brain Metastases from Breast Cancer.

Authors:  Vyshak Alva Venur; José Pablo Leone
Journal:  Int J Mol Sci       Date:  2016-09-13       Impact factor: 5.923

View more
  8 in total

1.  Local and systemic therapy in breast cancer patients with central nervous system metastases.

Authors:  Ninke E A Wellerdieck; Peter Wessels; Maartje Los; Gabe S Sonke; Ellen Tromp; Dieta Brandsma
Journal:  Breast Cancer Res Treat       Date:  2022-06-09       Impact factor: 4.872

2.  Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation.

Authors:  Yiling Zhang; Ningning Cui; Gang Zheng
Journal:  Oncol Lett       Date:  2020-01-08       Impact factor: 2.967

3.  Neoplastic cerebral aneurysm from triple-negative breast cancer: A case report.

Authors:  Eric S Nussbaum; Collin M Torok; Zena M Khalil; John M Pederson
Journal:  Surg Neurol Int       Date:  2021-05-03

4.  Serum-derived factors of breast cancer patients with brain metastases alter permeability of a human blood-brain barrier model.

Authors:  Carolin J Curtaz; Constanze Schmitt; Saskia-Laureen Herbert; Jonas Feldheim; Nicolas Schlegel; Fabien Gosselet; Carsten Hagemann; Norbert Roewer; Patrick Meybohm; Achim Wöckel; Malgorzata Burek
Journal:  Fluids Barriers CNS       Date:  2020-04-22

5.  Endocrine therapy for the treatment of leptomeningeal carcinomatosis in luminal breast cancer: a comprehensive review.

Authors:  Leonor Fernandes; Leonor Vasconcelos de Matos; Débora Cardoso; Marlene Saraiva; Renata Medeiros-Mirra; Andreia Coelho; Helena Miranda; Ana Martins
Journal:  CNS Oncol       Date:  2020-10-20

6.  Analysis of microRNAs in Exosomes of Breast Cancer Patients in Search of Molecular Prognostic Factors in Brain Metastases.

Authors:  Carolin J Curtaz; Leonie Reifschläger; Linus Strähle; Jonas Feldheim; Julia J Feldheim; Constanze Schmitt; Matthias Kiesel; Saskia-Laureen Herbert; Achim Wöckel; Patrick Meybohm; Malgorzata Burek
Journal:  Int J Mol Sci       Date:  2022-03-27       Impact factor: 5.923

Review 7.  Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.

Authors:  Seth A Wander; Neil O'Brien; Lacey M Litchfield; Declan O'Dea; Claudia Morato Guimaraes; Dennis J Slamon; Shom Goel
Journal:  Oncologist       Date:  2022-10-01       Impact factor: 5.837

Review 8.  Radiation Necrosis from Stereotactic Radiosurgery-How Do We Mitigate?

Authors:  Balamurugan A Vellayappan; Tresa McGranahan; Jerome Graber; Lynne Taylor; Vyshak Venur; Richard Ellenbogen; Andrew E Sloan; Kristin J Redmond; Matthew Foote; Samuel T Chao; John H Suh; Eric L Chang; Arjun Sahgal; Simon S Lo
Journal:  Curr Treat Options Oncol       Date:  2021-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.